Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Compass Therapeutics Inc (CMPX)

Compass Therapeutics Inc (CMPX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 985,355
  • Shares Outstanding, K 177,862
  • Annual Sales, $ 850 K
  • Annual Income, $ -49,380 K
  • EBIT $ -71 M
  • EBITDA $ -71 M
  • 60-Month Beta 1.44
  • Price/Sales 1,104.84
  • Price/Cash Flow N/A
  • Price/Book 4.48

Options Overview Details

View History
  • Implied Volatility 227.86% (-4.26%)
  • Historical Volatility 57.68%
  • IV Percentile 54%
  • IV Rank 21.96%
  • IV High 756.36% on 11/03/25
  • IV Low 79.11% on 08/13/25
  • Expected Move (DTE 14) 0.21 (3.84%)
  • Put/Call Vol Ratio 0.40
  • Today's Volume 21
  • Volume Avg (30-Day) 580
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 11,433
  • Open Int (30-Day) 14,248
  • Expected Range 5.32 to 5.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.10
  • Number of Estimates 7
  • High Estimate -0.08
  • Low Estimate -0.14
  • Prior Year -0.11
  • Growth Rate Est. (year over year) +9.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.78 +46.30%
on 11/06/25
5.86 -5.63%
on 12/01/25
+1.71 (+44.76%)
since 11/05/25
3-Month
3.28 +68.60%
on 09/22/25
5.86 -5.63%
on 12/01/25
+2.09 (+60.76%)
since 09/05/25
52-Week
1.33 +315.79%
on 04/01/25
5.86 -5.63%
on 12/01/25
+4.00 (+261.44%)
since 12/05/24

Most Recent Stories

More News
Compass Therapeutics to Participate in Upcoming December Investor Events

BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today...

CMPX : 5.53 (-0.18%)
Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Based on a continuing trend of decreased mortality in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), the...

CMPX : 5.53 (-0.18%)
Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

CTX-10726 demonstrated potent, simultaneous inhibition of tumor angiogenesis and PD-1-mediated immune suppression, and eliminated tumors in multiple preclinical studies. In vivo, CTX-10726 outperformed...

CMPX : 5.53 (-0.18%)
Compass Therapeutics to Participate in Upcoming November Investor Events

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based...

CMPX : 5.53 (-0.18%)
Compass Therapeutics to Participate in Upcoming September Investor Events

BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based...

CMPX : 5.53 (-0.18%)
Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering

BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based...

CMPX : 5.53 (-0.18%)
Compass Therapeutics Announces Proposed Public Offering

BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based...

CMPX : 5.53 (-0.18%)
Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

In the ongoing Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer, fewer deaths have been observed than originally projected. We believe this...

CMPX : 5.53 (-0.18%)
Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025

BOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, will...

CMPX : 5.53 (-0.18%)
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

CMPX : 5.53 (-0.18%)

Business Summary

Compass Therapeutics Inc. is a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematologic malignancies. The company's lead product candidate includes CTX-471. Compass Therapeutics Inc. is based...

See More

Key Turning Points

3rd Resistance Point 5.95
2nd Resistance Point 5.84
1st Resistance Point 5.69
Last Price 5.53
1st Support Level 5.43
2nd Support Level 5.32
3rd Support Level 5.17

See More

52-Week High 5.86
Last Price 5.53
Fibonacci 61.8% 4.13
Fibonacci 50% 3.60
Fibonacci 38.2% 3.06
52-Week Low 1.33

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar